Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Larimar Therapeutics Analyst Ratings
Oppenheimer Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $26
Wedbush Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $22
H.C. Wainwright Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $15
Larimar Therapeutics Initiated at Buy by HC Wainwright & Co.
Larimar Therapeutics Price Target Announced at $14.00/Share by Jones Trading
JonesTrading Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $14
Larimar Therapeutics Analyst Ratings
Baird Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $16
Analysts Offer Insights on Healthcare Companies: 2seventy Bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)
Buy Rating Affirmed: Larimar Therapeutics' Strategic Expansion and Promising Clinical Progress
Buy Rating for Larimar Therapeutics Backed by Promising Gene Therapy Advances for Friedreich's Ataxia
J.P. Morgan Securities: Reiterated the Larimar Therapeutics (LRMR.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $25.00.
Larimar Therapeutics Analyst Ratings
Citi: Maintaining the Larimar Therapeutics (LRMR.US) rating, adjusted from buy to buy rating, and adjusted the target price from $10.00 to $14.00.
Larimar Therapeutics Analyst Ratings
Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14
J.P. Morgan Securities: The Larimar Therapeutics (LRMR.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $25.00.
Larimar Therapeutics Analyst Ratings